This data suggests that, unless BIN1-induced cancer-cell death depends on TP53, pharmacological activation of a less mutated cell death-promoting gene, such as BIN1, would be a more realistic strategy to eradicate cisplatin-resistant cancer cells than activating the TP53 gene that might be already dysfunctional due to a gene mutation. Here, TP53 is linked to cancer.